Physician profile
Alexa Meitz
NPI 1255040788
$3,784.53
in general payments reported to CMS, 2019-2025
26 companies · $2,095 in 2025
The $2,095 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $597 · 2024: $1,092 · 2025: $2,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,784.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,161.91 | 2023-2025 | |
| Madrigal Pharmaceuticals | $320.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $302.06 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $271.78 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $243.18 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $174.20 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $168.03 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $155.18 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.85 | 2023-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $141.77 | 2024-2025 | |
| Vivus LLC | $127.31 | 2023-2025 | Pancreaze |
| Pfizer INC. | $75.66 | 2025 | |
| Novo Nordisk INC | $71.58 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $69.32 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $63.74 | 2023-2025 | Ocaliva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.81 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $37.93 | 2024 | Suflave, Sutab |
| Mirum Pharmaceuticals, INC. | $33.54 | 2024 | Livmarli |
| Ferring Pharmaceuticals INC. | $33.33 | 2025 | Rebyota |
| Exact Sciences Corporation | $24.32 | 2024 | Cologuard Collection Kit |
| Axonics, INC. | $22.09 | 2024 | Axonics |
| Nestle Healthcare Nutrition INC. | $21.89 | 2023 | |
| Gilead Sciences, INC. | $21.65 | 2025 | |
| Fresenius Kabi USA, LLC | $18.01 | 2023 | Idacio |
| Boston Scientific Corporation | $17.53 | 2025 | Overstitch Endoscopic Suturing System |
| Alnylam Pharmaceuticals INC. | $15.63 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Meitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.